Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
Department of Section for Perioperative Medicine and Intensive Care, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.
J Neurotrauma. 2020 Jun 15;37(12):1381-1391. doi: 10.1089/neu.2019.6741. Epub 2020 Mar 6.
Brain protein biomarker clearance to blood in traumatic brain injury (TBI) is not fully understood. The aim of this study was to analyze the effect that a disrupted blood-brain barrier (BBB) had on biomarker clearance. Seventeen severe TBI patients admitted to Karolinska University Hospital were prospectively included. Cerebrospinal fluid (CSF) and blood concentrations of S100 calcium binding protein B (S100B) and neuron-specific enolase (NSE) were analyzed every 6-12 h for ∼1 week. Blood and CSF albumin were analyzed every 12-24 h, and BBB integrity was assessed using the CSF:blood albumin quotient (Q). We found that time-dependent changes in the CSF and blood levels of the two biomarkers were similar, but that the correlation between the biomarkers and Q was lower for NSE (ρ = 0.444) than for S100B (ρ = 0.668). Because data were longitudinal, we also conducted cross correlation analyses, which indicated a directional flow and lag-time of biomarkers from CSF to blood. For S100B, this lag-time could be ascribed to BBB integrity, whereas for NSE it could not. Upon inferential modelling, using generalized least square estimation (S100B) or linear mixed models (NSE), Q ( = 0.045), time from trauma ( < 0.001), time from trauma ( = 0.023), and CSF biomarker levels ( = 0.008) were independent predictors of S100B in blood. In contrast, for NSE, only time from trauma was significant ( < 0.001). These findings are novel and important, but must be carefully interpreted because of different characteristics between the two proteins. Nonetheless, we present the first data that indicate that S100B and NSE are cleared differently from the central nervous system, and that both the disrupted BBB and additional alternative pathways, such as the recently described glymphatic system, may play a role. This is of importance both for clinicians aiming to utilize these biomarkers and for the pathophysiological understanding of brain protein clearance, but warrants further examination.
颅脑创伤(TBI)患者脑内蛋白标志物向血液中的清除机制尚未完全阐明。本研究旨在分析血脑屏障(BBB)破坏对标志物清除的影响。17 例严重 TBI 患者前瞻性纳入本研究。患者伤后 1 周内每 6-12 小时采集 1 次脑脊液(CSF)和血液标本,检测 S100 钙结合蛋白 B(S100B)和神经元特异性烯醇化酶(NSE)浓度;每 12-24 小时采集 1 次血液和 CSF 白蛋白,用 CSF 与血液白蛋白比值(Q)评估 BBB 完整性。我们发现,两种标志物的 CSF 和血液水平随时间的变化趋势相似,但 NSE(ρ=0.444)与 Q 的相关性低于 S100B(ρ=0.668)。由于数据是纵向的,我们还进行了交叉相关分析,结果提示标志物从 CSF 向血液的流动呈方向性,且存在滞后时间。对于 S100B,滞后时间可能归因于 BBB 的完整性,而对于 NSE 则不然。基于广义最小二乘估计(S100B)或线性混合模型(NSE)的推断性建模结果表明,Q(=0.045)、创伤发生后的时间( < 0.001)、创伤发生后的时间( = 0.023)和 CSF 生物标志物水平( = 0.008)是血液中 S100B 的独立预测因子。相比之下,对于 NSE,只有创伤发生后的时间有显著影响( < 0.001)。这些发现是新颖且重要的,但由于两种蛋白的特性不同,需要谨慎解释。尽管如此,我们首次提供了数据,表明 S100B 和 NSE 从中枢神经系统中清除的方式不同,且 BBB 破坏以及其他替代途径(如最近描述的糖质淋系统)可能发挥作用。这对于旨在利用这些生物标志物的临床医生以及对脑内蛋白清除的病理生理学理解都很重要,但还需要进一步研究。